Landscape of PD-1/PD-L1 Regulation and Targeted Immunotherapy

作     者：Jieming Ni Anping Ni 

作者机构：Seven Year Program of China Medical UniversityShenyang 110122China Department of Clinical LaboratoriesPeking Union Medical College HospitalChinese Academy of Medical Sciences&Peking Union Medical CollegeBeijing 100730China 

出 版 物：《Chinese Medical Sciences Journal》 (中国医学科学杂志（英文版）)

年 卷 期：2018年第33卷第3期

页      面：174-182页

核心收录：

学科分类：1002[医学-临床医学] 10[医学] 

主　　题：programmed cell death protein 1/programmed death ligand 1 immunotherapy regulation clinical trial inhibitors 

摘      要：Programmed cell death protein 1(PD-1)/programmed death ligand 1(PD-L1)is a significant immune checkpoint,and the dysfunction of this axis contributes to tumor metastasis and immune ***3K/Akt/mTOR and MAPK signal network induces PD-1/PD-L1 expression and facilitates tumor *** factors such as hypoxia induced factors,PTEN,p53,CDK5,BRD4,STAT modulate PD-1/PDL1 ***-1/PD-L1 level is also regulated via epigenetic and post-translational *** underlying mechanisms mentioned above may provide potential targets for tumor *** present,the combination therapy of PD-1/PD-L1 monoclonal antibodies plus small molecular inhibitors has achieved good outcomes in tumor treatment.